ABNOM
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
relevance score : -100.0%
ReferencesKo te Q‑switched Nd:YAG laser e mōhiotia ana hei rongoā mō ngā nevus o Ota me ngā āhuatanga ōrite. I whakahaerehia e mātou he rangahau ki te arotake i te whaihua o te laser high‑fluence 1064 nm Q‑switched Nd:YAG i ngā wāhi Mongolian i ngā wāhi rereke, kāore i te maama te kiri. I rangahauhia e mātou ngā turoro 61 me ēnei wāhi, i tirotirohia te katoa o ngā whiu e 70. Ko te haurua o ngā patunga i rongoahia ki te laser, ko ētahi i waiho kia kore e rongoa mō te whakataurite. I arotakehia e mātou ngā hua mā te whakamahi i te tauine me te taputapu e kīia nei ko te Mexameter® hei ine i ngā taumata melanin. I whaihia ngā turoro mō te toharite o ngā marama 14 i roto i te rōpū maimoatanga, me ngā marama 18 i roto i te rōpū tirotiro. I te mutunga o te rangahau, i kitea e mātou he rerekētanga nui i roto i ngā tatauranga tauine me ngā taumata melanin i waenga i te rōpū rongoā, te rōpū kāore i te rongoā, me te rōpū laser‑whakaritea e whakaatu ana i ngā hua pai ake. Ko te taiaho high‑fluence Q‑switched Nd:YAG, me te kore e maama te kiri, i kitea he whaihua me te haumaru mō te rongoā i ēnei wāhi rereke o Mongolian.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
I ako mātou i te whaihua me te haumaru o te whakamahi i tētahi maimoatanga laser motuhake mō te ABNOM, me te titiro ki ngā mea ka pā ki te pai o te mahi. I titiro mātou ki ngā turoro 110, he ABNOM ka whiwhi i waenga i te rua me te iwa ngā maimoatanga laser. I kitea e mātou he pai ake te mahi o te maimoatanga i te roa o te mahi, engari kāore i te pai ki ngā turoro pakeke. He pai ake te mahi mō ngā turoro he kiri māma ake (momo III) me ngā wāhi iti ake i pangia (iti iho i te 10 cm²). Ko te melasma me te ABNOM ka iti ake te whai hua o te maimoatanga. Ko te tae me te maha o ngā wāhi kua pā ki te āhua kāore i rereke. Tata ki te 10 % o ngā turoro he wāhi pōuri ake i muri i te maimoatanga. He pai ngā hua o te maimoatanga maha. Ko ngā turoro tawhito, te kiri pōuri, me ngā wāhi pōuri ka kaha ake te whiwhi i ngā wāhi pōuri i muri i te maimoatanga. Mō ngā turoro me te ABNOM me te rewharewha, he pai ake te whakamahi i te taiaho iti‑kaha ki te karo i te kino o te rewharewha.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Maimoatanga
He iti rawa te awhina a ngā kai‑māma. Kāore i rite ki te melasma; ka taea te whakapai ake i te ABNOM mā te maimoatanga laser, ka waiho kia tangohia me te kore e hoki mai anō. Ka taea te mahi maimoatanga taiaho 10 ki te 20 wā hei rongoā i te ABNOM.
#QS1064 laser